Have you lost money investing in Humanigen? If yes, please visit us Class action lawsuit brought by shareholders of Humanigen, Inc or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.

NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP, a nationally recognized investor rights law firm, is reminding investors of the deadline for filing a motion by lead plaintiff in a securities class action lawsuit filed on behalf of investors holding the securities of Humanigen, Inc. (“Humanigen” or the “Company”) purchased or acquired HGEN in between May 28, 2021 and July 12, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the District of New Jersey alleging violations of the Securities Exchange Act of 1934.

Humanigen is a clinical-stage biopharmaceutical company focused on preventing and treating an overreaction of the immune system called “cytokine storm,” a physiological response in which the immune system suddenly causes an uncontrolled and excessive release of pro-inflammatory signaling molecules called cytokines Release in large quantities can lead to multisystem organ failure and death. The company’s lead product candidate is its proprietary antibody lenzilumab, which is being developed, among other things, to treat cytokine storm associated with COVID-19.

Among other studies, Humanigen is evaluating lenzilumab for the treatment of hospitalized COVID-19 patients in the ACTIV-5/BET-B study, which is part of a direct public-private partnership with the National Institutes of Health (“NIH”).

In May 2021, Humanigen submitted an emergency use authorization application for lenzilumab to the U.S. Food and Drug Administration (“FDA”) for the treatment of patients hospitalized with COVID-19 (the “Lenzilumab EUA”).

Plaintiff alleges that throughout the Class Period, Defendants made materially false and misleading statements. Specifically, Plaintiff alleges that…